Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Fulvestrant (Primary) ; G1T 38 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 09 Aug 2017 According to a G1 Therapeutics media release, preliminary phase 1b data from this trial is expected in the second quarter of 2018.
- 07 Jan 2017 Status changed from not yet recruiting to recruiting.
- 09 Dec 2016 New trial record